Cargando…

Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD

INTRODUCTION: Tolvaptan is used to treat autosomal dominant polycystic kidney disease (ADPKD) because it inhibits binding of the antidiuretic hormone vasopressin to the vasopressin V2 receptor (V2R), which suppresses the insertion of preformed water channel aquaporin 2 (AQP2) molecules in the lumina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makabe, Shiho, Manabe, Shun, Kataoka, Hiroshi, Akihisa, Taro, Yoshida, Rie, Ushio, Yusuke, Sato, Masayo, Tsuchiya, Ken, Mochizuki, Toshio, Nitta, Kosaku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418978/ https://www.ncbi.nlm.nih.gov/pubmed/34514204 http://dx.doi.org/10.1016/j.ekir.2021.06.033

Ejemplares similares

Germline Mutations for Kidney Volume in ADPKD
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

Prediction of Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease Using PKD1/PKD2 Mutations
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

High Serum Phosphate Level as a Risk Factor to Determine Renal Prognosis in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Study
por: Sato, Masayo, et al.
Publicado: (2020)

Impact of kidney function and kidney volume on intracranial aneurysms in patients with autosomal dominant polycystic kidney disease
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease
por: Aoyama, Yumi, et al.
Publicado: (2020)

Visceral to subcutaneous fat ratio as an indicator of a ≥30% eGFR decline in chronic kidney disease
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

Maximum Carotid Intima-Media Thickness in Association with Renal Outcomes
por: Manabe, Shun, et al.
Publicado: (2021)

Machine learning for morbid glomerular hypertrophy
por: Ushio, Yusuke, et al.
Publicado: (2022)

Sex Differences in Time-Series Changes in Pseudo-R(2) Values Regarding Hyperuricemia in Relation to the Kidney Prognosis
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

Maximum Glomerular Diameter and Oxford MEST-C Score in IgA Nephropathy: The Significance of Time-Series Changes in Pseudo-R(2) Values in Relation to Renal Outcomes
por: Kataoka, Hiroshi, et al.
Publicado: (2019)

Autosomal Dominant Polycystic Kidney Disease with Emphysematous Polycystic Renal Infection That Required Surgical Treatment
por: Watanabe, Kentaro, et al.
Publicado: (2018)

Time series changes in pseudo-R(2) values regarding maximum glomerular diameter and the Oxford MEST-C score in patients with IgA nephropathy: A long-term follow-up study
por: Kataoka, Hiroshi, et al.
Publicado: (2020)

Glomerular Basement Membrane Protein Expression and the Diagnosis and Prognosis of Autosomal Dominant Alport Syndrome
por: Akihisa, Taro, et al.
Publicado: (2019)

PKD1 mutation may epistatically ameliorate nephronophthisis progression in patients with NPHP1 deletion
por: Watanabe, Saki, et al.
Publicado: (2019)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies: Not Just in Fabry Disease
por: Manabe, Shun, et al.
Publicado: (2021)

Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report
por: Kataoka, Hiroshi, et al.
Publicado: (2019)

Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients
por: Bargagli, Matteo, et al.
Publicado: (2021)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach
por: Rigato, Matteo, et al.
Publicado: (2022)

Proximal Tubulopathy With Fibrillary Inclusions: A Rare Manifestation of Lymphoma-Associated Monoclonal Gammopathy of Renal Significance (MGRS)
por: Ino, Ayami, et al.
Publicado: (2019)

Impacts of Sex Differences in Pulse Pressure among Patients with Chronic Kidney Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2019)

Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload
por: Suzuki, Shunji, et al.
Publicado: (2018)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)

Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
por: Mallett, Andrew J., et al.
Publicado: (2021)

Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Sekine, Akinari, et al.
Publicado: (2022)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease
por: Iwabuchi, Yuko, et al.
Publicado: (2018)

Slowly Progressive Male Alport Syndrome Evaluated by Serial Biopsy: Importance of Type IV Collagen Staining
por: Sato, Masayo, et al.
Publicado: (2021)

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life
por: Todorova, Polina, et al.
Publicado: (2023)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
por: Barnawi, Rashid A, et al.
Publicado: (2018)

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study
por: Schirutschke, Holger, et al.
Publicado: (2021)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Urinary Biomarkers at Early ADPKD Disease Stage
por: Petzold, Katja, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o04kbbv5ricfv9gvm5ds8d51kt